MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes and survival rates among glioblastoma patients.
Metablok (LSALT peptide) is our lead drug candidate for treating inflammation in the lungs, liver and kidneys..
Arch believes Metablok has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role. In August 2019, a scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins published a paper in the journal Cell describing a novel mechanism of action for organ inflammation. In the publication, the enzyme dipeptidase-1 was identified as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. In the same publication, dipeptidase-1 was shown to be the target of Metablok.
Arch is pursuing clinical development of Metablok to treat acute injury in the lungs, kidneys and liver caused by inflammation.
Arch is currently preparing a Phase II Trial to investigate Metablok’s efficacy in the prevention of multiple organ injuries in patients with COVID-19. In the worst cases of COVID-19 infection, fatalities are often linked to severe acute lung inflammation and subsequent respiratory failure, or acute kidney injury and renal failure.
AB569: Treatment for Drug Resistant Bacterial Infections
AB569 is a new drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs. It also has potential to be modified for use in other indications, including adaptation as a topical cream for bacterial skin infections.
AB569 has a mechanism of action that differs from the mechanism of action of antibiotics. AB569 has orphan drug status from the U.S. FDA for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. AB569 has orphan medicinal product designation from the European Medicines Agency for the treatment of cystic fibrosis.
Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics to generate new materials that display new surface properties.